Evidence map›Paper›PMID 19267176›Full record

ArticleEuropean child & adolescent psychiatry2009

Amisulpride treatment of adolescent patients with schizophrenia or schizo-affective disorders.

Fatma Varol Tas, Taner Guvenir

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in European child & adolescent psychiatry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Fatma Varol TasDepartments of Child and Adolescent Psychiatry, University of Dokuz Eylul, 35340 Balcova, Izmir, Turkey. fvaroltas@hotmail.com
Taner Guvenir
Dokuz Eylül University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this article, our aim was to share our clinical experience regarding the effectiveness and the side effects of amisulpride treatment in adolescent cases. We reviewed all the cases who had amisulpride treatment during their stay in a newly opened in-patient unit, and three female cases who had undergone amisulpride treatment. We observed that the drug was effective and caused side effects like galactorrhea due to increased prolactin levels, which were not severe enough to terminate the treatment. Our clinical experience provides preliminary evidence that amisulpride might be an effective antipsychotic drug for adolescent cases. However, it caused considerable side effects.

Indexed as

AdolescentAmisulprideAntiparkinson AgentsAntipsychotic AgentsBiperidenDose-Response Relationship, DrugDrug Administration ScheduleDrug MonitoringDrug Therapy, CombinationFemaleGalactorrheaHumansPsychotic DisordersSchizophreniaSulpirideTreatment OutcomeAmisulprideAntiparkinson AgentsAntipsychotic AgentsBiperidenSulpiride

Identifiers

PMID19267176
OpenAlexW1964604688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.